26 Apr 2021 - Praemium Limited (ASX:PPS) CEO and Managing Director Michael Ohanessian talks about the company's strong 1H21 results, the successful acquisition of Powerwrap, platform enhancements and outlook.
23 Apr 2021 - Theta Gold Mines Limited (ASX:TGM, OTCQB:TGMGF) CEO for Africa, Mitford Mundell, talks about the company's projects and its plans to bring open-pit mining to historical underground mines and exploit old workings.
23 Apr 2021 - Sequoia Financial Group Limited (ASX:SEQ) Managing Director Garry Crole discusses the company's FY21 profit update and guidance.
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
16 Apr 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook talks about the growing demand for digital payments and the opportunities this presents for the company.
06 Apr 2021 - LaserBond Limited (ASX:LBL) CEO Wayne Hooper talks about the company's strong 1H21 results despite the impact of COVID-19, its focus on growth opportunities to expand its national footprint, and business strategy, including potential growth via acquisitions.
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.
29 Mar 2021 - XTEK Limited (ASX:XTE) Managing Director Phillipe Odouard talks 1H21 results, discussing the company's expanded operational capacity to meet demand for its high-value proprietary solutions in a favourable market environment for domestic and global defence industries.
29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.
